FDA has approved Imfinzi (durvalumab), in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
